The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 May 25

PMID 38790900

Authors

Robert J Gil

Adam Kern

Krystian Bojko

Aneta Gziut-Rudkowska

Dobrin Vassilev

Jacek Bil

Affiliations

Soon will be listed here.

Abstract

This multicenter, randomized study aimed to compare the sirolimus-eluting BiOSS LIM C dedicated coronary bifurcation stent with second-generation -limus drug-eluting stents (rDESs) in the treatment of non-left main (non-LM) coronary bifurcation. The deployment of a single stent in the main vessel-main branch across a side branch was the default strategy in all patients. The primary endpoint was the rate of major cardiovascular events (cardiac death, myocardial infarction, and target lesion revascularization) at 48 months. We enrolled 230 patients, allocating 116 patients to the BiOSS LIM C group and 114 patients to the rDES group. Most procedures were elective (BiOSS vs. rDES: 48.3% vs. 59.6%, = 0.09) and performed in bifurcations within the left anterior descending/diagonal branch (BiOSS vs. rDES: 51.7% vs. 61.4%, = 0.15). At 48 months, there were no statistically significant differences between the BiOSS and rDES groups in terms of major adverse cardiovascular events (MACE), cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR) as follows: MACEs-18.1% vs. 14.9%, HR 1.36, 95% CI 0.62-2.22, and = 0.33; cardiac death-4.3% vs. 3.5%, HR 1.23, 95% CI 0.33-4.56, and = 0.75; MI-2.6% vs. 3.5%, HR 0.73, 95% CI 0.17-3.23, and = 0.68; and TLR-11.2% vs. 7.9%, HR 1.66, 95% CI 0.75-3.71, and = 0.21. The implantation success rate of the BiOSS LIM C stent was very high, and the cumulative MACE rates were promising. The POLBOS 3 trial sets an important benchmark for treating non-LM coronary bifurcations (ClinicalTrials.gov NCT03548272).

References

Gil R, Bil J, Dzavik V, Vassilev D, Kern A, Formuszewicz R . Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial. Can J Cardiol. 2015; 31(5):671-8. DOI: 10.1016/j.cjca.2014.12.024. View

Bil J, Gil R, Pawlowski T, Milewski K . Assessment of vascular response to BiOSS LIM C stents vs Orsiro stents in the porcine coronary artery model. Cardiovasc Ther. 2017; 35(4). DOI: 10.1111/1755-5922.12267. View

Pan M, Lassen J, Burzotta F, Ojeda S, Albiero R, Lefevre T . The 17th expert consensus document of the European Bifurcation Club - techniques to preserve access to the side branch during stepwise provisional stenting. EuroIntervention. 2023; 19(1):26-36. PMC: 10173756. DOI: 10.4244/EIJ-D-23-00124. View

Thygesen K, Alpert J, Jaffe A, Chaitman B, Bax J, Morrow D . Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018; 138(20):e618-e651. DOI: 10.1161/CIR.0000000000000617. View

Gil R, Bil J, Grundeken M, Kern A, Inigo Garcia L, Vassilev D . Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial. EuroIntervention. 2015; 12(11):e1404-e1412. DOI: 10.4244/EIJY15M11_11. View

Gil R, Kern A, Formuszewicz R, Inigo Garcia L, Dobrzycki S, Vassilev D . 6-year results of BiOSS stents in coronary bifurcation treatment. Eur J Clin Invest. 2021; 51(8):e13555. DOI: 10.1111/eci.13555. View

Derimay F, Aminian A, Lattuca B, Souteyrand G, Maillard L, Alvain S . One year results of coronary bifurcation revascularization with the re-POT provisional sequential technique. The CABRIOLET registry. Int J Cardiol. 2023; 397:131632. DOI: 10.1016/j.ijcard.2023.131632. View

Ungureanu C, Natalis A, Cocoi M, Dumitrascu S, Noterdaeme T, Gach O . The impact of the bifurcation angle for the Nano-Crush two-stent coronary bifurcation technique on long-term outcomes in a real-world clinical population. Cardiovasc Revasc Med. 2024; 64:54-59. DOI: 10.1016/j.carrev.2024.02.017. View

Buysschaert I, Dubois C, Dens J, Ormiston J, Worthley S, McClean D . Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention. 2013; 9(5):573-81. DOI: 10.4244/EIJV9I5A93. View

10.

Laraichi Z, Faraj R, Fellat N . The POT-PUFF Sign: A New Angiographic Indicator of Stent Malapposition During Proximal Optimization Therapy. Cureus. 2023; 15(8):e43552. PMC: 10502443. DOI: 10.7759/cureus.43552. View

11.

Bennett J, Adriaenssens T, McCutcheon K, Dens J, Desmet W, Sinnaeve P . 5-Year clinical follow-up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents) study. Catheter Cardiovasc Interv. 2018; 92(6):E375-E380. DOI: 10.1002/ccd.27597. View

12.

Takagi K, Ielasi A, Basavarajaiah S, Chieffo A, Shannon J, Godino C . The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: the Milan and New-Tokyo (MITO) Registry. Catheter Cardiovasc Interv. 2013; 84(3):341-8. DOI: 10.1002/ccd.25178. View

13.

Lu H, Bekker R, Grundeken M, Woudstra P, Wykrzykowska J, Tijssen J . Five-year clinical follow-up of the STENTYS self-apposing stent in complex coronary anatomy: a single-centre experience with report of specific angiographic indications. Neth Heart J. 2018; 26(5):263-271. PMC: 5910317. DOI: 10.1007/s12471-018-1111-7. View

14.

Mohamed M, Polad J, Hildick-Smith D, Bizeau O, Baisebenov R, Roffi M . Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry. EuroIntervention. 2020; 16(7):603-612. DOI: 10.4244/EIJ-D-20-00361. View

15.

Grundeken M, Wykrzykowska J, Ishibashi Y, Garg S, de Vries T, Garcia-Garcia H . First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv. 2015; 87(7):E248-60. DOI: 10.1002/ccd.26344. View

16.

Albiero R, Burzotta F, Lassen J, Lefevre T, Banning A, Chatzizisis Y . Treatment of coronary bifurcation lesions, part I: implanting the first stent in the provisional pathway. The 16th expert consensus document of the European Bifurcation Club. EuroIntervention. 2022; 18(5):e362-e376. PMC: 10259243. DOI: 10.4244/EIJ-D-22-00165. View

17.

Chen S, Zhang Y, Xu B, Ye F, Zhang J, Tian N . Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique. EuroIntervention. 2012; 8(7):803-14. DOI: 10.4244/EIJV8I7A123. View

18.

Gupta A, Shrivastava A, Chhikara S, Mamas M, Vijayvergiya R, Swamy A . Optical Coherence Tomography Predictors of SIde Branch REstenosis after unprotected Left Main bifurcation angioplasty using double kissing crush technique (OP-SIBRE LM Study). Catheter Cardiovasc Interv. 2023; 103(1):51-60. DOI: 10.1002/ccd.30915. View

19.

de la Torre Hernandez J, Alfonso F, Sanchez Recalde A, Jimenez Navarro M, de Prado A, Hernandez F . Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry). Am J Cardiol. 2013; 111(5):676-83. DOI: 10.1016/j.amjcard.2012.11.019. View

20.

Gil R, Pawlowski T, Legutko J, Lesiak M, Witkowski A, Gasior M . Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent. Medicine (Baltimore). 2019; 98(14):e15106. PMC: 6455659. DOI: 10.1097/MD.0000000000015106. View